Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy

Ahmet Bilgehan Şahin, Erdem Cubukcu, Birol Ocak, Adem Deligonul, Sibel Oyucu Orhan, Sahsine Tolunay, Mustafa Sehsuvar Gokgoz, Sibel Cetintas, Gorkem Yarbas, Kazım Senol, Mehmet Refik Goktug, Zeki Burak Yanasma, Ulviyya Hasanzade, Turkkan Evrensel, Ahmet Bilgehan Şahin, Erdem Cubukcu, Birol Ocak, Adem Deligonul, Sibel Oyucu Orhan, Sahsine Tolunay, Mustafa Sehsuvar Gokgoz, Sibel Cetintas, Gorkem Yarbas, Kazım Senol, Mehmet Refik Goktug, Zeki Burak Yanasma, Ulviyya Hasanzade, Turkkan Evrensel

Abstract

Blood-based biomarkers reflect systemic inflammation status and have prognostic and predictive value in solid malignancies. As a recently defined biomarker, Pan-Immune-Inflammation-Value (PIV) integrates different peripheral blood cell subpopulations. This retrospective study of collected data aimed to assess whether PIV may predict the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in Turkish women with breast cancer. The study consisted of 743 patients with breast cancer who were scheduled to undergo NAC before attempting cytoreductive surgery. A pre-treatment complete blood count was obtained in the two weeks preceding NAC, and blood-based biomarkers were calculated from absolute counts of relevant cell populations. The pCR was defined as the absence of tumor cells in both the mastectomy specimen and lymph nodes. Secondary outcome measures included disease-free survival (DFS) and overall survival (OS). One hundred seven patients (14.4%) had pCR. In receiver operating characteristic analysis, optimal cut-off values for the neutrophile-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte (PLR), PIV, and Ki-67 index were determined as ≥ 2.34, ≥ 0.22, ≥ 131.8, ≥ 306.4, and ≥ 27, respectively. The clinical tumor (T) stage, NLR, MLR, PLR, PIV, estrogen receptor (ER) status, human epidermal growth factor receptor-2 (HER-2) status, and Ki-67 index were significantly associated with NAC response in univariate analyses. However, multivariate analysis revealed that the clinical T stage, PIV, ER status, HER-2 status, and Ki-67 index were independent predictors for pCR. Moreover, the low PIV group patients had significantly better DFS and OS than those in the high PIV group (p = 0.034, p = 0.028, respectively). Based on our results, pre-treatment PIV seems as a predictor for pCR and survival, outperforming NLR, MLR, PLR in predicting pCR in Turkish women with breast cancer who received NAC. However, further studies are needed to confirm our findings.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Figure 1
Figure 1
Kaplan-Meier plots of survival endpoints in different Pan-Immune-Inflammation-Value (PIV) groups (low versus high): (A) disease-free survival; (B) overall survival.
Figure 2
Figure 2
Flowchart of patients selection.

References

    1. Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog. Mol. Biol. Transl. Sci. 2017;151:1–32. doi: 10.1016/bs.pmbts.2017.07.002.
    1. Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin. Obstet. Gynecol. 2016;59:651–672. doi: 10.1097/GRF.0000000000000239.
    1. Doval DC, Dutta K, Batra U, Talwar V. Neoadjuvant chemotherapy in breast cancer: Review of literature. J. Indian Med. Assoc. 2013;111:629–631.
    1. Mathew J, et al. Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions. Eur. J. Surg. Oncol. 2009;35:113–122. doi: 10.1016/j.ejso.2008.03.015.
    1. National Comprehensive Cancer Network. Breast Cancer. Version 5.2021. Available at: .
    1. Spring LM, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin. Cancer Res. 2020;26:2838–2848. doi: 10.1158/1078-0432.CCR-19-3492.
    1. Parekh T, Dodwell D, Sharma N, Shaaban AM. Radiological and pathological predictors of response to neoadjuvant chemotherapy in breast cancer: A brief literature review. Pathobiology. 2015;82:124–132. doi: 10.1159/000433582.
    1. Guthrie GJK, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013;88:218–230. doi: 10.1016/j.critrevonc.2013.03.010.
    1. Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J. Leukoc. Biol. 2019;106:309–322. doi: 10.1002/JLB.4RI0818-311R.
    1. Huong PT, Nguyen LT, Nguyen XB, Lee SK, Bach DH. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. Cancers (Basel) 2019;11:240. doi: 10.3390/cancers11020240.
    1. Dupré A, Malik HZ. Inflammation and cancer: What a surgical oncologist should know. Eur. J. Surg. Oncol. 2018;44:566–570. doi: 10.1016/j.ejso.2018.02.209.
    1. Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2014;106:dju124. doi: 10.1093/jnci/dju124.
    1. Gu L, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: Evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:31926–31942. doi: 10.18632/oncotarget.7876.
    1. Templeton AJ, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 2014;23:1204–1212. doi: 10.1158/1055-9965.EPI-14-0146.
    1. Ni XJ, et al. An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. PLoS ONE. 2014;9:e111886. doi: 10.1371/journal.pone.0111886.
    1. Asano Y, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann. Surg. Oncol. 2016;23:1104–1110. doi: 10.1245/s10434-015-4934-0.
    1. Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, Vásquez-Trespalacios E. Platelet-To-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS ONE. 2018;13:e0207224. doi: 10.1371/journal.pone.0207224.
    1. Fucà G, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: Results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br. J. Cancer. 2020;123:403–409. doi: 10.1038/s41416-020-0894-7.
    1. Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: Going pro. Cancers (Basel) 2019;11:564. doi: 10.3390/cancers11040564.
    1. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277–286. doi: 10.1016/j.ccr.2013.02.013.
    1. Marech I, et al. Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients. J. Cell. Mol. Med. 2016;20:1373–1380. doi: 10.1111/jcmm.12826.
    1. Shibutani M, et al. The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: A retrospective study. BMC Cancer. 2017;17:1–7. doi: 10.1186/s12885-017-3395-1.
    1. Shigeta K, et al. High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Ann. Surg. Oncol. 2016;23:4115–4122. doi: 10.1245/s10434-016-5354-5.
    1. Amo L, et al. Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1. Front. Oncol. 2014;4:245. doi: 10.3389/fonc.2014.00245.
    1. Schmied L, Höglund P, Meinke S. Platelet-mediated protection of cancer cells from ımmune surveillance: Possible ımplications for cancer ımmunotherapy. Front. Immunol. 2021;12:640578. doi: 10.3389/fimmu.2021.640578.
    1. Taucher S, et al. Impact of pre-treatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost. 2003;89:1098–1106. doi: 10.1055/s-0037-1613413.
    1. Chen SC, Wu PC, Wang CY, Kuo PL. Evaluation of cytotoxic T lymphocyte-mediated anticancer response against tumor interstitium-simulating physical barriers. Sci. Rep. 2020;10:1–13. doi: 10.1038/s41598-019-56847-4.
    1. Eryilmaz MK, et al. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac. J. Cancer Prev. 2014;15:7737–7740. doi: 10.7314/APJCP.2014.15.18.7737.
    1. Eren T, et al. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients. Medicine (Baltimore) 2020;99:e20346. doi: 10.1097/MD.0000000000020346.
    1. Caziuc A, Schlanger D, Amarinei G, Dindelegan GC. Neutrophils-to-lymphocytes, lymphocytes to-monocytes and platelets-to-lymphocytes ratios: Predictive biomarkers for response to neoadjuvant chemotherapy in breast cancer. J. BU ON. 2020;25:182–187.
    1. Ma Y, Zhang J, Chen X. Lymphocyte-to-monocyte ratio is associated with the poor prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Cancer Manag. Res. 2021;13:1571–1580. doi: 10.2147/CMAR.S292048.
    1. Peng Y, et al. Low pre-treatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients. Cancer Biol. Ther. 2020;21:189–196. doi: 10.1080/15384047.2019.1680057.
    1. Hu Y, et al. Platelet/lymphocyte ratio is superior to neutrophil/lymphocyte ratio as a predictor of chemotherapy response and disease-free survival in luminal B-like (HER2−) breast cancer. Clin. Breast Cancer. 2020;20:e403–e409. doi: 10.1016/j.clbc.2020.01.008.
    1. Suppan C, et al. Neutrophil/lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. BMC Cancer. 2015;15:1–8. doi: 10.1186/s12885-015-2005-3.
    1. Graziano V, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38. doi: 10.1016/j.breast.2018.12.014.
    1. Kim HY, Kim TH, Yoon HK, Lee A. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting neoadjuvant chemotherapy response in breast cancer. J. Breast Cancer. 2019;22:425–438. doi: 10.4048/jbc.2019.22.e41.
    1. Guven DC, et al. PILE: A candidate prognostic score in cancer patients treated with immunotherapy. Clin. Transl. Oncol. 2021 doi: 10.1007/s12094-021-02560-6.
    1. Fucà G, et al. The pan-immune-inflammation value in patients with metastatic melanoma receiving first-line therapy. Target. Oncol. 2021 doi: 10.1007/s11523-021-00819-0.
    1. Ligorio F, et al. The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2): Positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers (Basel) 2021;13:1964. doi: 10.3390/cancers13081964.
    1. Du Q, et al. PD-L1 acts as a promising immune marker to predict the response to neoadjuvant chemotherapy in breast cancer patients. Clin. Breast Cancer. 2020;20:e99–e111. doi: 10.1016/j.clbc.2019.06.014.
    1. Gao Z, Li C, Liu M, Jiang J. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: A meta-analysis. BMC Cancer. 2020;20:1–14. doi: 10.1186/s12885-019-6169-0.
    1. Boland MR, et al. Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer: systematic review and meta-analysis. Br. J. Surg. 2021;108:24–31. doi: 10.1093/bjs/znaa048.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel